Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare
Buy Rating Affirmed for Spero Therapeutics Amidst Drug Pipeline Progress and Strategic Partnerships
Analysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)
Spero Therapeutics (SPRO.US): The 2024 Q1 financial report achieved revenue of $9.267 million, previous value of USD 2.069 million, expected value of USD 21.53 million; earnings per share were -0.24 USD, previous value of -0.25 USD, and expected value of
Spero Therapeutics (SPRO.US): The 2024 Q1 financial report achieved revenue of $9.267 million, previous value of USD 2.069 million, expected value of USD 21.53 million; earnings per share were -0.24 USD, previous value of -0.25 USD, and expected value of -0.04 USD.
Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.04) by 500 percent. This is a 4 percent increase over losses of $(0.2
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M
04:09 PM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M
Spero Therapeutics | 10-Q: Quarterly report
Press Release: Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
Spero Therapeutics 1Q Loss/Shr 24c >SPRO
Spero Therapeutics 1Q Loss/Shr 24c >SPRO
Spero Therapeutics 1Q Rev $9.27M >SPRO
Spero Therapeutics 1Q Rev $9.27M >SPRO
Shareholders in Spero Therapeutics (NASDAQ:SPRO) Are in the Red If They Invested Three Years Ago
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatm
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare
Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics
Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics with a Overweight.
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics with a Buy and maintains $7 price target.
Spero Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/18/2024 300% HC Wainwright & Co. → $7 Reiterates Buy → Buy 11/14/2023 300% HC Wainwright & Co. → $7 Rei
Spero Therapeutics' Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating
Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Spero Therapeutics Files $300M Mixed Securities Shelf
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?